Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.71 USD
+0.02 (0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.70 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
AVIR 3.71 +0.02(0.54%)
Will AVIR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AVIR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AVIR
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade
AVIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
Other News for AVIR
Commit To Buy Atea Pharmaceuticals At $2.50, Earn 8.3% Annualized Using Options
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Atea Pharmaceuticals completes patient enrollment in Phase 3 SUNRISE-3 trial
Atea Pharmaceuticals: Balancing Promising Prospects with Clinical and Regulatory Risks
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update